Protagonist Therapeutics, Inc. (PTGX): Price and Financial Metrics

Protagonist Therapeutics, Inc. (PTGX): $7.85

-0.76 (-8.83%)

POWR Rating

Component Grades














  • PTGX scores best on the Value dimension, with a Value rank ahead of 48.04% of US stocks.
  • The strongest trend for PTGX is in Value, which has been heading down over the past 179 days.
  • PTGX's current lowest rank is in the Stability metric (where it is better than 8.75% of US stocks).

PTGX Stock Summary

  • Of note is the ratio of Protagonist Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 7.02% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for Protagonist Therapeutics Inc is higher than it is for about merely 8.69% of US stocks.
  • PTGX's price/sales ratio is 44.42; that's higher than the P/S ratio of 95.79% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Protagonist Therapeutics Inc are ENTA, NRIX, CNCE, SGMO, and RVMD.
  • PTGX's SEC filings can be seen here. And to visit Protagonist Therapeutics Inc's official web site, go to

PTGX Valuation Summary

  • PTGX's price/earnings ratio is -28.3; this is 177.53% lower than that of the median Healthcare stock.
  • Over the past 62 months, PTGX's price/sales ratio has gone NA NA.
  • Over the past 62 months, PTGX's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for PTGX.

Stock Date P/S P/B P/E EV/EBIT
PTGX 2021-08-31 84.7 6.5 -28.3 -26.1
PTGX 2021-08-30 81.7 6.2 -27.3 -25.0
PTGX 2021-08-27 83.6 6.4 -27.9 -25.7
PTGX 2021-08-26 82.4 6.3 -27.5 -25.3
PTGX 2021-08-25 85.7 6.5 -28.6 -26.4
PTGX 2021-08-24 86.8 6.6 -29.0 -26.7

PTGX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PTGX has a Quality Grade of D, ranking ahead of 12.65% of graded US stocks.
  • PTGX's asset turnover comes in at 0.07 -- ranking 291st of 682 Pharmaceutical Products stocks.
  • RGNX, MBIO, and MTEM are the stocks whose asset turnover ratios are most correlated with PTGX.

The table below shows PTGX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.070 1 -0.571
2021-06-30 0.088 1 -0.513
2021-03-31 0.117 1 -0.538
2020-12-31 0.127 1 -0.678
2020-09-30 0.140 1 -0.800
2020-06-30 0.100 1 -0.977

PTGX Price Target

For more insight on analysts targets of PTGX, see our PTGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $31.75 Average Broker Recommendation 1.44 (Moderate Buy)

PTGX Stock Price Chart Interactive Chart >

Price chart for PTGX

PTGX Price/Volume Stats

Current price $7.85 52-week high $50.54
Prev. close $8.61 52-week low $7.49
Day low $7.49 Volume 1,652,500
Day high $8.40 Avg. volume 1,019,900
50-day MA $18.89 Dividend yield N/A
200-day MA $29.67 Market Cap 381.95M

Protagonist Therapeutics, Inc. (PTGX) Company Bio

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded in 2006 and is based in Milpitas, California.

PTGX Latest News Stream

Event/Time News Detail
Loading, please wait...

PTGX Latest Social Stream

Loading social stream, please wait...

View Full PTGX Social Stream

Latest PTGX News From Around the Web

Below are the latest news stories about Protagonist Therapeutics Inc that investors may wish to consider to help them evaluate PTGX as an investment opportunity.

3 Desirable Drug Stocks With Very Promising Pipelines

Drug makers with superb pipelines are likely to deliver great returns for long-term investors.

Larry Ramer on InvestorPlace | February 16, 2022

Protagonist Therapeutics (PTGX) Soars 5%: Is Further Upside Left in the Stock?

Protagonist Therapeutics (PTGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | February 16, 2022

Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17th at 3:00 p.m. EST.

Yahoo | February 10, 2022

We're Hopeful That Protagonist Therapeutics (NASDAQ:PTGX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | February 7, 2022

Protagonist Is Still Being Undervalued Like There's Real Risk

Investment Thesis: Protagonist Is a Very Strong Near-Term Prospect Looking to Make a Real Shakeup of the Treatment of PV Investors got spooked big time when Protagonist Therapeutics (PTGX) announced a clinical hold on their lead peptide therapeutic rusfertide, with share prices dropping almost 75%. Of course, once the hold...

Galzus Research on Seeking Alpha | February 1, 2022

Read More 'PTGX' Stories Here

PTGX Price Returns

1-mo -59.43%
3-mo -68.41%
6-mo -77.59%
1-year -75.06%
3-year -26.01%
5-year -25.87%
YTD -77.05%
2021 69.64%
2020 185.96%
2019 4.75%
2018 -67.64%
2017 -5.41%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5735 seconds.